Addendum
Dostarlimab (endometrial cancer) - Addendum to Project A23-143
Report documents
-
Addendum
Dostarlimab (endometrial cancer) - Addendum to Project A23-143
Dossier assessment
Indication:
Adult patients with mismatch repair deficient / microsatellite instability‑high primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy
Result of dossier assessment:
After addendum now:
- Patients with primary FIGO stage III: added benefit not proven
- Patients with primary FIGO stage IV: hint of minor added benefit
- Patients with recurrent disease: indication of major added benefit
Additional information
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.
Project details
- Project no.
- A24-59
- Commission
- Commission awarded on 07.05.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-59_en
Connected Projects
-
Dossier assessment
Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed